Nxera Pharma KK

4565

Equity

ISIN JP3431300007 / Valor 1892568

Tokyo Stock Exchange (2024-09-18)

JPY 1,299.00+2.69%

Nxera Pharma KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Nxera Pharma KK, previously known as Sosei Heptares, is a biopharmaceutical company leveraging advanced technology to develop specialty medicines aimed at addressing unmet medical needs both in Japan and globally. The company has a robust pipeline of over 30 active programs, ranging from discovery to late clinical stages, which are being developed internally and through partnerships with leading pharmaceutical and biotech firms. These programs target critical areas such as neurology, gastrointestinal and immunological disorders, metabolic diseases, and rare conditions. Central to Nxera Pharma's innovation is its proprietary GPCR-targeted structure-based drug discovery platform, "NxWave," which facilitates the creation of potentially best- or first-in-class therapeutic candidates. The company operates with a workforce of over 350 employees across key locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is publicly traded on the Tokyo Stock Exchange under the ticker 4565.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Nxera Pharma KK reported a significant increase in revenue for the first half of FY2024, reaching ¥12,720 million ($84 million), compared to ¥2,146 million ($16 million) in the same period of the previous year. This growth was primarily driven by the inclusion of PIVLAZ® sales in Japan, a new 'option to license' transaction with Boehringer Ingelheim, and several milestone payments from partners such as Neurocrine, Centessa, and AbbVie.

Core Operating Profit

For the first half of FY2024, Nxera Pharma KK achieved a core operating profit of ¥1,176 million ($8 million), a significant turnaround from a core operating loss of ¥2,720 million ($20 million) in the prior comparative period. This improvement was mainly due to the increased revenue, although it was partially offset by higher costs, including additional core costs related to the inclusion of Nxera Pharma Japan and Nxera Pharma Korea in the scope of consolidation.

Operating Loss

Despite the increase in revenue, Nxera Pharma KK reported an operating loss of ¥3,654 million ($24 million) for the first half of FY2024, compared to ¥4,168 million ($31 million) in the same period last year. The operating loss was influenced by non-core costs such as amortization charges on intangible assets, PIVLAZ® inventory adjustments, and integration costs.

Cash Balance

As of June 30, 2024, Nxera Pharma KK maintained a robust cash balance of ¥51 billion ($317 million). This strong cash position ensures sufficient investment capacity to support ongoing and future business operations and strategic initiatives.

Financial Outlook

Nxera Pharma KK has provided guidance for the full year FY2024, with expected R&D expenses ranging from ¥12,000 to ¥14,000 million and S&M plus G&A expenses between ¥18,000 to ¥20,000 million. The company plans to continue investing in R&D activities, integration costs, and the commercialization of key products to drive long-term growth.

Summarized from source with an LLMView Source

Key figures

-18.2%1Y

-35.8%3Y

-41.5%5Y

Performance

42.8%1Y

51.3%3Y

49.8%5Y

Volatility